Zhi Tong Cai Jing·2025-09-09 06:17Core Viewpoint - Zhaoyan New Drug (603127) experienced a decline of over 7%, with a current price of 20.98 HKD and a trading volume of 147 million HKD [1] Group 1: Shareholder Reduction Plans - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through Shanghai Stock Exchange transactions, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - Previously, on September 1, the company disclosed that former Vice Chairman Zuo Conglin planned to reduce his holdings from August 19, 2025, to August 29, 2025, with a maximum reduction of 3,524,500 shares, which was 0.4703% of the company's total share capital at that time [2] - As of August 29, 2025, Zuo Conglin had reduced his holdings by 2,264,900 shares through concentrated bidding, completing his reduction plan [2]